The potentially toxic nature of intravesical BCG is illustrated by two patients who developed profound systemic illness with fever, rash, basal crackles, and bilateral shadowing on the chest radiograph after treatment.
The first case in this report, with a miliary pattern on the chest radiograph, liver and spleen disease, and pancytopenia with a granulomatous bone marrow, showed more widespread dissemination than previously reported from intravesical BCG. The pattern of granulomatous inflammation suggests haematogenous spread, though a hypersensitivity reaction cannot be excluded.6 Our second case shows for the first time granulomatous inflammation of the lung with diffuse lung injury, in keeping with the adult respiratory distress syndrome. As mycobacteria were not identified either by acid fast stains or cultures, we cannot firmly determine the mechanism of this process.
Although infrequent, the cases presented and others that have been reported indicate that intravesical BCG may result in appreciable toxicity. Such complications appear to be responsive to standard antituberculous treatment with or without the addition of corticosteroids.2 5 6 It has been proposed that severe systemic complications may be prevented by prophylactic isoniazid given for three days with each BCG treatment.5 This hypothesis has not been formally tested and it is not known whether prophylactic isoniazid might interfere with the antitumour effect of intravesical BCG. 
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